| Code | Description | Claims | Beneficiaries | Total Paid |
| J2350 |
Injection, ocrelizumab, 1 mg |
1,467 |
1,322 |
$39.25M |
| J9271 |
Injection, pembrolizumab, 1 mg |
2,331 |
1,827 |
$21.49M |
| J2323 |
Injection, natalizumab, 1 mg |
1,224 |
1,174 |
$7.14M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
20,568 |
13,657 |
$3.35M |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
713 |
447 |
$2.74M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
16,945 |
14,182 |
$2.56M |
| J9312 |
Injection, rituximab, 10 mg |
430 |
306 |
$2.51M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
1,662 |
976 |
$2.36M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
26,764 |
10,470 |
$2.15M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
302 |
200 |
$2.10M |
| 96415 |
|
6,663 |
5,186 |
$1.69M |
| 77386 |
|
4,977 |
694 |
$1.68M |
| J0897 |
Injection, denosumab, 1 mg |
966 |
883 |
$1.62M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
1,582 |
1,389 |
$1.58M |
| 77412 |
|
4,111 |
674 |
$1.44M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
495 |
328 |
$1.32M |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
722 |
567 |
$1.17M |
| 77336 |
|
3,678 |
1,880 |
$1.13M |
| J0485 |
Injection, belatacept, 1 mg |
1,450 |
730 |
$1.02M |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
1,369 |
859 |
$909K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
355 |
125 |
$855K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
1,979 |
1,401 |
$784K |
| 80053 |
Comprehensive metabolic panel |
56,713 |
36,611 |
$777K |
| J9299 |
Injection, nivolumab, 1 mg |
177 |
102 |
$773K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
7,042 |
6,085 |
$595K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
20,882 |
10,204 |
$579K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
2,847 |
1,708 |
$567K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
4,421 |
2,577 |
$538K |
| J0185 |
Injection, aprepitant, 1 mg |
3,014 |
2,061 |
$535K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
28,549 |
7,813 |
$480K |
| 76641 |
|
6,477 |
4,227 |
$456K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
450 |
171 |
$452K |
| J1756 |
Injection, iron sucrose, 1 mg |
9,405 |
4,545 |
$442K |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
292 |
280 |
$440K |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
90 |
72 |
$419K |
| J9035 |
Injection, bevacizumab, 10 mg |
114 |
74 |
$414K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
217 |
152 |
$400K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
1,582 |
1,458 |
$380K |
| 96416 |
|
1,703 |
1,032 |
$363K |
| 36430 |
|
2,388 |
1,531 |
$336K |
| 31575 |
|
864 |
832 |
$335K |
| 77300 |
|
1,187 |
1,007 |
$307K |
| 36415 |
Collection of venous blood by venipuncture |
51,616 |
25,379 |
$289K |
| 96417 |
|
4,570 |
2,989 |
$281K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
2,561 |
1,804 |
$277K |
| 77334 |
|
1,196 |
946 |
$260K |
| J9070 |
Cyclophosphamide, 100 mg |
600 |
426 |
$236K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
59,459 |
39,120 |
$230K |
| 77066 |
Tomosynthesis, mammo |
2,338 |
1,979 |
$228K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
6,365 |
3,848 |
$221K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,850 |
2,321 |
$205K |
| 96409 |
|
1,949 |
1,273 |
$192K |
| 10005 |
|
487 |
476 |
$190K |
| 83615 |
|
15,224 |
9,152 |
$170K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
7,011 |
6,040 |
$160K |
| 77301 |
|
237 |
229 |
$156K |
| 77065 |
Tomosynthesis, mammo |
2,018 |
1,723 |
$156K |
| 88185 |
|
707 |
655 |
$153K |
| 96367 |
|
2,904 |
2,499 |
$144K |
| 96411 |
|
2,225 |
1,538 |
$140K |
| 96401 |
|
1,715 |
1,101 |
$137K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
13,630 |
12,323 |
$129K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,791 |
2,083 |
$122K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,749 |
2,450 |
$114K |
| 76642 |
|
2,192 |
1,742 |
$114K |
| 86850 |
|
5,074 |
3,020 |
$110K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
1,106 |
1,094 |
$106K |
| 77290 |
|
272 |
247 |
$106K |
| 93017 |
|
1,807 |
1,781 |
$105K |
| 96402 |
|
2,175 |
2,029 |
$99K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
47,657 |
20,316 |
$80K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
197 |
195 |
$71K |
| J9264 |
Injection, paclitaxel protein-bound particles, 1 mg |
40 |
12 |
$71K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
1,320 |
786 |
$71K |
| 36591 |
|
1,783 |
1,489 |
$67K |
| 77062 |
|
2,127 |
1,831 |
$65K |
| 77338 |
|
322 |
289 |
$64K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
944 |
937 |
$63K |
| 86901 |
|
5,089 |
3,026 |
$58K |
| J9267 |
Injection, paclitaxel, 1 mg |
2,098 |
1,053 |
$56K |
| 77280 |
|
162 |
152 |
$54K |
| 82728 |
|
5,301 |
4,699 |
$52K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
729 |
511 |
$48K |
| 86945 |
|
1,818 |
1,110 |
$44K |
| 86900 |
|
5,093 |
3,027 |
$43K |
| 96523 |
|
1,007 |
881 |
$42K |
| 86480 |
|
783 |
764 |
$41K |
| 77061 |
|
1,271 |
1,112 |
$40K |
| 82378 |
|
3,072 |
2,556 |
$39K |
| J9045 |
Injection, carboplatin, 50 mg |
1,749 |
1,121 |
$39K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
281 |
248 |
$37K |
| 77080 |
|
1,271 |
1,095 |
$36K |
| J3490 |
Unclassified drugs |
2,486 |
1,576 |
$35K |
| 87497 |
|
1,339 |
905 |
$35K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
59 |
49 |
$34K |
| 84703 |
|
8,451 |
6,988 |
$32K |
| 77332 |
|
194 |
181 |
$32K |
| 82784 |
|
2,016 |
1,736 |
$31K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
1,933 |
1,181 |
$31K |
| 83883 |
|
1,748 |
1,398 |
$27K |
| J7050 |
Infusion, normal saline solution, 250 cc |
14,156 |
8,525 |
$26K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
413 |
365 |
$26K |
| 86923 |
|
1,390 |
1,003 |
$26K |
| 71250 |
|
1,906 |
1,884 |
$24K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,405 |
2,946 |
$24K |
| 83735 |
|
5,651 |
3,487 |
$23K |
| 87799 |
|
426 |
229 |
$22K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
2,103 |
1,824 |
$21K |
| J9190 |
Injection, fluorouracil, 500 mg |
1,739 |
1,048 |
$21K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
162 |
111 |
$21K |
| C8908 |
Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral |
66 |
56 |
$19K |
| 77049 |
|
63 |
55 |
$19K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
608 |
387 |
$18K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,753 |
1,435 |
$17K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
659 |
608 |
$17K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
9,640 |
5,614 |
$17K |
| 88184 |
|
450 |
422 |
$17K |
| 82607 |
|
1,608 |
1,547 |
$16K |
| 84439 |
|
2,188 |
1,844 |
$16K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
79 |
70 |
$15K |
| 86334 |
|
1,147 |
978 |
$15K |
| 96377 |
|
633 |
510 |
$15K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
9,514 |
5,200 |
$15K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
774 |
744 |
$14K |
| 86304 |
|
995 |
817 |
$14K |
| 99195 |
|
140 |
117 |
$14K |
| 88172 |
|
360 |
351 |
$14K |
| 82746 |
|
1,566 |
1,509 |
$14K |
| J9370 |
Vincristine sulfate, 1 mg |
1,373 |
954 |
$13K |
| 96368 |
|
860 |
544 |
$13K |
| 84100 |
|
3,794 |
2,645 |
$12K |
| 86300 |
|
819 |
748 |
$12K |
| 85730 |
|
2,364 |
2,055 |
$11K |
| J9206 |
Injection, irinotecan, 20 mg |
326 |
209 |
$11K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
115 |
93 |
$11K |
| 86301 |
|
767 |
613 |
$10K |
| 83540 |
|
2,563 |
2,341 |
$10K |
| 85045 |
|
3,940 |
3,343 |
$10K |
| 88173 |
|
374 |
363 |
$10K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,259 |
1,150 |
$10K |
| 85610 |
|
2,602 |
2,262 |
$10K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
5,835 |
2,472 |
$9K |
| 83550 |
|
2,359 |
2,150 |
$9K |
| 84165 |
|
1,453 |
1,249 |
$8K |
| S0028 |
Injection, famotidine, 20 mg |
5,217 |
3,288 |
$8K |
| 81003 |
|
4,368 |
3,436 |
$8K |
| 86769 |
|
327 |
291 |
$8K |
| 80061 |
Lipid panel |
610 |
569 |
$8K |
| 86140 |
|
2,279 |
2,086 |
$8K |
| 84153 |
|
667 |
605 |
$7K |
| 86803 |
|
869 |
842 |
$7K |
| 86706 |
|
919 |
882 |
$7K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
444 |
241 |
$7K |
| 77295 |
|
36 |
12 |
$7K |
| 86704 |
|
833 |
800 |
$6K |
| 85652 |
|
3,304 |
2,972 |
$6K |
| 80076 |
|
600 |
508 |
$6K |
| 90686 |
|
433 |
423 |
$6K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
367 |
297 |
$5K |
| 82948 |
|
1,633 |
1,337 |
$5K |
| J2785 |
Injection, regadenoson, 0.1 mg |
155 |
154 |
$5K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
274 |
247 |
$5K |
| 86790 |
|
281 |
275 |
$5K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
6,857 |
4,843 |
$5K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
144 |
79 |
$4K |
| 87340 |
|
752 |
723 |
$4K |
| J1626 |
Injection, granisetron hydrochloride, 100 mcg |
1,819 |
852 |
$4K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
241 |
235 |
$4K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
317 |
239 |
$3K |
| G0008 |
Administration of influenza virus vaccine |
230 |
226 |
$3K |
| 83021 |
|
200 |
196 |
$3K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
47 |
35 |
$3K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
25 |
25 |
$3K |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
158 |
84 |
$3K |
| 99201 |
|
70 |
70 |
$3K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
838 |
541 |
$3K |
| J2916 |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
122 |
50 |
$3K |
| C1889 |
Implantable/insertable device, not otherwise classified |
86 |
79 |
$2K |
| 85670 |
|
550 |
527 |
$2K |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
3,325 |
2,199 |
$2K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
246 |
184 |
$2K |
| 82550 |
|
437 |
380 |
$2K |
| 36416 |
|
121 |
116 |
$2K |
| 85379 |
|
281 |
254 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
413 |
405 |
$2K |
| 85240 |
|
121 |
113 |
$2K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
12 |
12 |
$2K |
| 80050 |
General health panel |
89 |
69 |
$1K |
| 83010 |
|
135 |
130 |
$1K |
| A4648 |
Tissue marker, implantable, any type, each |
92 |
89 |
$1K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
79 |
73 |
$1K |
| 86160 |
|
83 |
72 |
$1K |
| 84702 |
|
91 |
82 |
$1K |
| 84156 |
|
384 |
319 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,081 |
1,174 |
$1K |
| 84481 |
|
110 |
93 |
$975.02 |
| 84550 |
|
295 |
198 |
$963.19 |
| 85246 |
|
35 |
33 |
$929.57 |
| 82105 |
|
122 |
102 |
$886.22 |
| 80197 |
|
147 |
90 |
$874.38 |
| 82248 |
|
239 |
170 |
$811.98 |
| 88342 |
|
14 |
14 |
$781.74 |
| 90656 |
|
44 |
44 |
$721.21 |
| 71046 |
Radiologic examination, chest; 2 views |
28 |
27 |
$690.19 |
| C8937 |
Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure) |
31 |
27 |
$650.88 |
| 84480 |
|
51 |
41 |
$434.16 |
| 85384 |
|
64 |
49 |
$346.54 |
| 90662 |
|
15 |
15 |
$337.16 |
| 84466 |
|
30 |
28 |
$315.07 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
55 |
25 |
$309.12 |
| 84403 |
|
13 |
13 |
$296.82 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
59 |
56 |
$278.87 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
226 |
193 |
$213.39 |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
105 |
62 |
$210.08 |
| 85613 |
|
26 |
24 |
$193.10 |
| 85732 |
|
38 |
36 |
$161.52 |
| 85027 |
|
62 |
48 |
$156.28 |
| 81001 |
|
79 |
70 |
$147.29 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
40 |
25 |
$143.28 |
| 83690 |
|
33 |
26 |
$141.55 |
| 85303 |
|
12 |
12 |
$107.75 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
26 |
12 |
$91.90 |
| 85300 |
|
12 |
12 |
$77.78 |
| J3480 |
Injection, potassium chloride, per 2 meq |
80 |
37 |
$67.90 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
26 |
12 |
$65.36 |
| 82150 |
|
16 |
12 |
$63.61 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
139 |
100 |
$50.62 |
| 77417 |
|
22 |
12 |
$0.00 |